GermanyGermany

New findings pave the way for causative treatment of osteoporosis

18.05.2009

Berlin – German researchers have identified a novel molecular target that paves the way for causative therapy of osteoporosis, the most common bone disease of post-meno¬pausal women. It is estimated that 1 in 3 women and 1 in 12 men over the age of 50 worldwide have osteoporosis, which causes high healthcare costs because the reduction in bone mineral density in course of the disease leads to an increased risk of fracture. Together with colleagues from the Netherlands and the US, researchers under Professor Achim Leutz from Berlin-based Max-Delbruck Center for Molecular Medicine discovered now that the observed disequilibrium between bone-forming cells (osteoblasts) and bone-resorbing osteoclasts is caused by an imbalance of two differently translated forms of the CCAAT/enhancer-binding protein beta (C/EBPbeta), which regulate transcription of the mafB gene. The long form of C/EBP-beta (“LAP”) led to mafB-directed inhibition of osteoclast formation, the short one (LIP) activated the production of the bone resorbing cells. Rapamycin, an inhibitor of mTOR increased the ratio of LAP over LIP and inhibited osteoclastogenesis. The researchers said they now want to find alternative regulators of C/EBPbeta translation that don’t show the immunosuppressive effects of Rapamycin.

GermanyGermany

27.10.2011

Leverkusen - Bayer Pharma has a lucky streak. The pharma division of the German chemical giant announced positive Phase III results from regorafenib in colorectal cancer. “We are extremely encouraged by the result of this...

GermanyGermany

24.10.2011

Leverkusen - A short statement from the European Medicines Agency (EMA) and a big step for the German biotech Biofrontera. The agency issued a favourable opinion on Biofrontera's marketing approval application for its drug for...

GermanyGermany

14.10.2011

Leverkusen/San Francisco - Bayer HealthCare and Onyx Pharmaceuticals will not to court over Nevaxar. The two companies reached an agreement related to regorafenib, a late-stage oncology compound. Regorafenib is an oral...

GermanyGermany

11.10.2011

Ingelheim/Ridgefield –Boehringer Ingelheim’s COPD treatment Combivent Respimat has been approved by the U.S. Food and Drug Administration (FDA) for the US market. The new, propellant-free inhaler product for the beta adrenergic...

GermanyGermany

01.10.2011

Rostock – German researchers say overexpression of one of the 49 transport proteins that shuttle substances over the blood-brain barrier could be the key to treating Alzheimer’s disease. In mice, the group headed by Jens Pahnke...

GermanyGermany

27.09.2011

Rehovot/Monheim – Bayer Crop Science may be a step closer to introducing desirable traits in wheat. In the collaboration with Israeli Evogene Ltd. the German company has reached a milestone. Utilising Evogene‘s proprietary...

GermanyGermany

22.09.2011

Willich – Brasilian biopolymer producer Braskem and German bioplastics compounding specialist FKuR GmbH, have signed a compounding agreement for green polyethylene. The tailor-made product will be a first in Europe, according...

GermanyGermany

08.09.2011

Leverkusen - It was a black Tuesday for Bayer. After rumours were leaked out that the FDA has doubts over the German pharmaceutical company's potential blockbuster Xarelto, the shares temporarily dropped as much as 17 percent....

GermanyGermany

06.09.2011

Bad Homburg - German VC firm Creathor venture announced the first closing of its Creathor Venture Fund III. Now, the company is poised to mete out €51million of fresh capital to start-ups. Life science companies will be among the...

Displaying results 21 to 30 out of 454

< Previous 21-30 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-germany/browse/2/article/new-findings-pave-the-way-for-causative-treatment-of-osteoporosis.html

Events

All Events

Stock list

All quotes

TOP

  • BIOINVENT INTERNATIONAL AB (S)3.10 SEK9.15%
  • Allergy Therapeutics (UK)19.12 GBP6.94%
  • PHARMING (NL)0.48 EUR6.67%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • CHRONTECH PHARMA (S)0.07 SEK-12.50%

TOP

  • WILEX (D)3.15 EUR314.5%
  • SANTHERA (CH)68.55 CHF90.4%
  • ADDEX (CH)4.08 CHF82.1%

FLOP

  • MERCK KGAA (D)65.43 EUR-48.6%
  • HYBRIGENICS (F)1.83 EUR-26.8%
  • PROSENSA (NL)9.48 USD-25.2%

TOP

  • SANTHERA (CH)68.55 CHF3489.0%
  • GW PHARMACEUTICALS (UK)427.00 GBP729.1%
  • PAION (D)2.79 EUR316.4%

FLOP

  • CYTOS (CH)0.26 CHF-92.4%
  • EVOCUTIS (UK)0.21 GBP-91.8%
  • PROSENSA (NL)9.48 USD-68.0%

No liability assumed, Date: 25.07.2014

Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...


Current issue

All issues

Product of the week

Products